By becoming a supporter of the Breast Cancer Vaccine
The Breast Cancer Vaccine Fund giving form makes it easy to support promising research that could one day save countless lives.
News broke this year that a first-of-its-kind vaccine to prevent breast cancer has shown overwhelmingly favorable results in animal models, according to a study by researchers at Cleveland Clinic's Lerner Research Institute.
Now, anyone can join the ranks of supporters who, to date, have made 3,043 gifts totaling $360,784.50. The researchers found that a single vaccination with the antigen α-lactalbumin prevents breast cancer tumors from forming in mice, while also inhibiting the growth of already existing tumors. Human trials could begin within the next year. If successful, it would be the first vaccine to prevent breast cancer.
"We believe that this vaccine will someday be used to prevent breast cancer in adult women in the same way that vaccines prevent polio and measles in children," says Vincent Tuohy, PhD, the study's principal investigator and an immunologist in Cleveland Clinic's Lerner Research Institute Department of Immunology. "If it works in humans the way it works in mice, this will be monumental."
In the study, genetically cancer-prone mice were vaccinated – half with a vaccine containing α-lactalbumin and half with a vaccine that did not contain the antigen. None of the mice vaccinated with α-lactalbumin developed breast cancer, while all of the other mice did.
The U.S. Food and Drug Administration has approved two cancer-prevention vaccines, one against cervical cancer and one against liver cancer. However, these vaccines target viruses – the human papillomavirus (HPV) and the Hepatitis B virus (HBV) – not cancer formation. In terms of developing a preventive vaccine, cancer presents a quandary not posed by viruses.
While viruses are recognized as foreign invaders by the immune system, cancer is not. Rather, cancer is an overdevelopment of the body's own cells. Trying to vaccinate against this cell overgrowth effectively would be vaccinating against the recipient's own body, destroying healthy tissue.
The key, Dr. Tuohy says, is to find a target within the tumor that is not typically found in a healthy person. In the case of breast cancer, Dr. Tuohy and his research team targeted α-lactalbumin – a protein that is found in the majority of breast cancers, but is not found in healthy women, except during lactation. Therefore, the vaccine can rev up a woman's immune system to target α-lactalbumin – thus stopping tumor formation – without damaging healthy breast tissue.
The strategy would be to vaccinate women over 40 – when breast cancer risk begins to increase and pregnancy becomes less likely. (If a woman would become pregnant after being vaccinated, she would experience breast soreness and would likely have to choose not to breast feed.) For younger women with a heightened risk of breast cancer, the vaccine may be an option to consider instead of prophylactic radical mastectomy.
"Most attempts at cancer vaccines have targeted viruses, or cancers that have already developed," says Joseph Crowe, MD, Director of the Breast Center at Cleveland Clinic and holder of the Lula Zapis Endowed Chair to Support Breast Cancer Research. "Dr. Tuohy is not a breast cancer researcher; he's an immunologist, so his approach is completely different – attacking the tumor before it can develop. It's a simple concept, yet one that has not been explored until now."
Dr. Tuohy believes that the study’s findings go beyond breast cancer, providing insight into the development of vaccines to prevent other types of cancer. The results show that the antigen used in a cancer vaccine must meet several criteria: it must be overexpressed in the majority of targeted tumors, and it must not be found in normal tissue, except under specific, avoidable conditions (such as lactation).
To make a gift supporting Lerner Research Institute or any area of Cleveland Clinic, visit our secure giving site or call Institutional Relations and Development at 216.444.1245 or toll-free at 800.223.2273, ext. 41245.